Publication:
Guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents 2014, Thailand

0
0

Issued Date

2015

Resource Type

Article

File Type

application/pdf

ISSN

17426405

DOI

10.1186/s12981-015-0053-z

Other identifier(s)

2-s2.0-84928230979

Rights Holder(s)

Scopus

Bibliographic Citation

AIDS Research and Therapy. Vol 12, No.1 (2015)

Suggested Citation

Manosuthi W., Ongwandee S., Bhakeecheep S., Leechawengwongs M., Ruxrungtham K., Phanuphak P., Hiransuthikul N., Ratanasuwan W., Chetchotisakd P., Tantisiriwat W., Kiertiburanakul S., Avihingsanon A., Sukkul A., Anekthananon T., The Adults And Adolescents Committee Of The Thai National Hiv Guidelines Working Group Guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents 2014, Thailand. AIDS Research and Therapy. Vol 12, No.1 (2015). doi:10.1186/s12981-015-0053-z Retrieved from: https://hdl.handle.net/20.500.14740/6143

Title

Guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents 2014, Thailand

Author(s)

Manosuthi W.
 Ongwandee S.
 Bhakeecheep S.
 Leechawengwongs M.
 Ruxrungtham K.
 Phanuphak P.
 Hiransuthikul N.
 Ratanasuwan W.
 Chetchotisakd P.
 Tantisiriwat W.
 Kiertiburanakul S.
 Avihingsanon A.
 Sukkul A.
 Anekthananon T.
 The Adults And Adolescents Committee Of The Thai National Hiv Guidelines Working Group

Abstract

New evidence has emerged regarding when to commence antiretroviral therapy (ART), optimal treatment regimens, management of HIV co-infection with opportunistic infections, and management of ART failure. The 2014 guidelines were developed by the collaborations of the Department of Disease Control, Ministry of Public Health (MOPH) and the Thai AIDS Society (TAS). One of the major changes in the guidelines included recommending to initiating ART irrespective of CD4 cell count. However, it is with an emphasis that commencing HAART at CD4 cell count above 500 cell/mm3 is for public health, in term of preventing HIV transmission and personal benefit. In tuberculosis co-infected patients with CD4 cell counts ≤50 cells/mm3 or with CD4 cell counts >50 cells/mm3 who have severe clinical disease, ART should be initiated within 2 weeks of starting tuberculosis treatment. The preferred initial ART regimen in treatment naïve patients is efavirenz combined with tenofovir and emtricitabine or lamivudine. Plasma HIV viral load assessment should be done twice a year until achieving undetectable results; and will then be monitored once a year. CD4 cell count should be monitored every 6 months until CD4 cell count ≥350 cells/mm3 and with plasma HIV viral load <50 copies/mL; then it should be monitored once a year afterward. HIV drug resistance genotypic test is indicated when plasma HIV viral load >1,000 copies/mL while on ART. Ritonavir-boosted lopinavir or atazanavir in combination with optimized two nucleoside-analogue reverse transcriptase inhibitors is recommended after initial ART regimen failure. Long-term ART-related safety monitoring has also been included in the guidelines. © Manosuthi et al.; licensee BioMed Central.

Subject(s)

Abacavir
 Atazanavir plus ritonavir
 Darunavir
 Darunavir plus ritonavir
 Didanosine
 Dolutegravir
 Efavirenz
 Emtricitabine
 Indinavir
 Lamivudine
 Lamivudine plus zidovudine
 Lopinavir plus ritonavir
 Nevirapine
 Raltegravir
 Rilpivirine
 Stavudine
 Tenofovir
 Zidovudine
 Adolescent health
 Article
 CD4 lymphocyte count
 Cryptococcosis
 Drug substitution
 Drug treatment failure
 Drug withdrawal
 Highly active antiretroviral therapy
 Human
 Human immunodeficiency virus 1
 Human immunodeficiency virus 1 infection
 Laboratory test
 Mixed infection
 Opportunistic infection
 Pneumocystis pneumonia
 Practice guideline
 Priority journal
 Thailand
 Tuberculosis
 Unspecified side effect
 Virus load

View online Resources

Research Projects

Organizational Units

Journal Issue

URI

https://hdl.handle.net/20.500.14740/6143

Collections

Scopus: Year 1983-2021

Endorsement

Review

Supplemented By

Referenced By